Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - ceftriaxone (ceftriaxone sodium) - powder for solution for i/m injection - 1000mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

hankook korus pharm co. - ceftriaxone (ceftriaxone sodium) - powder for solution for i/m injection - 1000mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ceftriaxone sodium - powder for solution for injection - 2gram

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

cr gosun pharma - ceftriaxone (ceftriaxone sodium) - powder for solution for injection - 1000mg

United States - English - NLM (National Library of Medicine)

cardinal health - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - ceftriaxone 2 g

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftriaxone sodium, quantity: 2386.6 mg - injection, powder for - excipient ingredients: - indications: treatment for the following infections when caused by susceptible aerobic organisims: 1 lower respiratory tract infections. caused by strep.pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph.aureus, h.influenzae, h.parainfluenzae, klebsiella sp. (including k.pneumoniae). e.coli, e.aerogenes, p.mirabilis and serratia marcescens. 2 skin and skin structure infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, streptococcus group g, strep.pyogenes, strep.virdans, streptococcus sp. (excluding enterococci), peptostreptococcus sp., e.coli, e.cloacae, klebsiella sp. (including k.pneumoniae and k.oxytoca), p.mirabilis, m.morganii and s.marcescens. 3 urinary tract infections (complicated and uncomplicated). caused by e.coli, p.mirabilis, p.vulgaris, m.morganii and klebsiella sp. (including k.pneumoniea). 4 uncomplicated gonorrhoea (cervical/urethral and rectal). caused by n.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 bacterial septicaemia. caused by strep.pneumoniae, e.coli and h.influenzae. 6 bone infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, strep.pneumoniae, streptococcus sp. (excluding enterocci), e.coli, enterobacter sp., pmirabilis and k.pneumoniae. 7 joint infection. caused by methicillin sensitive staph.aureus, strep.pneumoniae, streptococcus sp. (excluding enterococci), e.coli, p.mirabilis, k.pneumoniae and enterobacter sp. 8 menigitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by h.influenzae type b, n.menigitidis, strep.pneumoniae or enterobacteriaceae pending culture and sensitivity results. 9 surgical prophylaxis. the preoperative administration of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients_undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures whic are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10susceptibility testing. before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its sussceptibility ot the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftriaxone sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftriaxone sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftriaxone sodium, quantity: 1193.3 mg - injection, powder for - excipient ingredients: - indications: treatment for the following infections when caused by susceptible aerobic organisms: 1 lower respiratory tract infections. caused by strep.pneumoniae, streptococcus sp. (excluding enterococci), methicillin sensitive staph.aureus, h.incluenzae, h.parain fluenzae, klebsiella sp. (including k.pneumoniae). e.coli, e. aerogenes, p.mirabilis and serratia marcescens. 2 skin and skin structure infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, streptococcus group g, strep.pyogenes, strep.viridans, streptococcus sp. (excluding enterococci), peptostreptococcus sp.,_(including k.pneumoniae and k.oxytoca), p.mirabilis, m.morganii and s.marcescens. 3 urinary tract infections (complicated and uncomplicated). caused by e.coli, p.mirabilis, p.vulgaris, m.morganii and klebsiella sp. (including k.pneumoniae). uncomplicated gonorrhoea (cervical/urethral and rectal) caused by n.gonorrhoeae, including both penicillinase and nonpenicillinase producing strains. 5 bacterial septicaemia. caused by strep.pneumoniae, e.coli and h.influenzae. 6 bone infections. caused by methicillin sensitive staph.aureus, methicillin sensitive staph.epidermidis, streptococcus group b, strep.pneumoniae., streptococcus sp._ 7 joint infections. caused by methicillin sensitive staph.aureus, strep.pneumoniae, streptococcus sp. (excluding enterococci), e.coli, p.mirabilis. k.pneumoniae and enterobacter sp. 8 meningitis. the initial treatment, as a single agent, of menigitis in children and immunocompetent adults when presumed or proven to be caused by h.influenzae type b, n.meningitidis, strep.pneumoniae or enterobacteriaceae pending culture and sensitivity results. 9 surgical prophylaxis . the preoperarive administraion of a single 1g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical_procedures which are classified as contaminated or potentially contaminated, and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted. 10 susceptibility testing. before instituting treatement with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ceftriaxone disodium 2158,54 mg - eq. ceftriaxone 2000 mg - powder for solution for infusion - 2 g - ceftriaxone (di)sodium - ceftriaxone